Experimental compound that blocks a cellular helper protein many worn-out cells rely on to survive, letting it selectively destroy aged "zombie" cells. In fast-aging mice it lowered these cells and delayed some signs of aging, but no human aging data exist. Its only human testing revealed meaningful gut, liver, and eye toxicity. Never approved; not available as a medicine. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT / AST (liver enzymes) | ~10–26 U/L | Detects liver injury, the key dose-limiting toxicity |
| Total bilirubin | 0.3–1.0 mg/dL | Flags impaired liver clearance |
| Complete blood count | Neutrophils >1.5 ×10⁹/L; platelets >150 ×10⁹/L | Detects bone-marrow suppression |
| eGFR (kidney filtration) | >90 mL/min/1.73m² | Kidney clearance affects drug exposure |
| Corrected QT interval (QTc) | <440 ms | Screens for heart-rhythm risk, a class concern |
| Left-ventricular ejection fraction (LVEF) | ≥55% | Confirms adequate heart pumping before use |
| Dilated eye (retinal) exam | No retinal changes | Screens for ocular toxicity of the drug class |
Cadence: Liver enzymes and blood counts before each course and roughly weekly during active dosing; kidney function and electrocardiogram before each course; eye exam at baseline and promptly with any visual symptom, otherwise every 3–6 months during repeated use.